← Analysis page  ·  Uzo Capital hub  ·  Research hub

Actionable insights — Comstock, Liberty Stream & Merlin

The repeatable analysis behind the picks: not what he owns, but how he sizes and underwrites it — written so the process can be rerun later on different names.
2026-JUN-22 · Contrarian Codex (interview) · Uzo (Uzo Capital) · ▶ Watch (Patreon) · full analysis · transcript
How to read this page: each insight is a method — the way he constructs the book, the test that turns an idea into a position, and the signal to watch when re-running it. The boxed line shows how it played out in this appearance. (Timestamps reference the members-only Patreon recording; they aren't click-deep-linkable.)

3:35 1. Barbell the book — compounders vs call-options, sized by rule

The repeatable method
  1. Split the portfolio into two buckets: a slug of cheap, cash-generating, growing compounders, and a bucket of high-variance bets treated like call options (warrants, LEAPs, or pre-revenue early-stage names).
  2. Enter the option-like names small (2–3%) and let winners run; manage risk through position sizing, not stop-losses.
  3. When the option bucket balloons (a few names go up multiples), don't add — "rob from Peter to pay Paul," trimming to keep neither bucket out of whack.
  4. Be "ruthless about never adding to" an options position — the going-to-zero probability is real and ever-present.
Here: ~half his names had a 40–50% drawdown at some point this year and he treats that as par for the course; the early-stage sleeve (MRLN) is sized like VC while the cash-flow sleeve anchors the book.
Watch for

11:22 2. Underwrite the multi-year DCF — isolate the one variable that matters

The repeatable method
  1. Judge risk-reward against the outlook one-to-three years out, not today; a company is worth its multi-year future cash flow, not the next 12 months.
  2. Separate structural from cyclical: identify the one multi-year swing variable and largely ignore near-term noise around it.
  3. Weight your attention to risks that "permeate beyond a 12-month horizon"; near-term uncertainty is usually already in the price.
Here: for LIB he cared about the structural lithium-supply risk (the "sodium" question) over near-term "indigestion," and bought before lithium re-rated — the multi-year thesis, not the next few months.
Watch for

13:45 3. Avoid reflexive cash-burners — map the funding ladder

The repeatable method
  1. Screen out explorers and pre-cash-flow names where the next step must be funded by raising capital — a missed milestone makes dilution reflexive (low price → bigger raise → more dilution).
  2. If you do own one, map every funding step and the "timer" on it; a screw-up at any step compounds.
  3. Prefer businesses already generating cash or with assets they can sell to self-fund the next step.
Here: the whole thesis on LODE rests on cash coming "through the door" (the mining-claim sale) to kill the dilution "bogeyman" before the next metals/real-estate step.
Watch for

30:37 4. Asset-coverage — get the operating business (and its options) for free

The repeatable method
  1. Value the saleable / independent assets on their own (here: the land, the mining claims) against the whole enterprise value.
  2. If the cash those assets could realize approaches or exceeds the entire EV, you're buying the operating business — plus any call options — for nothing.
  3. Then the only thing you must underwrite is that the "free" business clears a low bar (doesn't burn cash / reaches profitability), with the scale of the upside as the debate.
Here: the LODE land alone is plausibly worth more than the market cap, so at ~$4 "you're virtually getting metals for free" — plus the LODE Bioleum lottery ticket on top.
Watch for

36:40 5. The vertical-integration test — does it capture the refining step?

The repeatable method
  1. For a recycling/processing business, ask where the economics leak: shipping intermediate product to a third-party refiner can hand away half the margin.
  2. Reward in-house refining/extraction — it lets the tipping fee be cut hard while protecting unit economics, and forces any competitor to solve both the processing plant and the refining (a double moat).
  3. Distinguish "does it work at all" (de-risked once a pilot runs) from "how profitable does it scale" — the latter is where the multi-bagger lives.
Here: LODE's in-house extraction (vs shipping to refiners in Brazil/Korea/China) is the durability case — one site at 70–80% utilization already makes the stock cheap; new sites are "a cherry on top."
Watch for

43:25 6. The financing-unlock catalyst — the offtake re-rates the capital stack

The repeatable method
  1. For a pre-scale producer, recognize the re-rating trigger is rarely the product — it's securing an offtake that unlocks cheaper capital.
  2. An offtake enables project-level debt (instead of diluting at the parent), pref financing that can convert at a later up-listing, and a lower cost of capital from a US listing / re-domicile.
  3. Grade the offtake's shape: a multi-year deal with floor pricing (uranium-style) is worth far more than a rolling three-month spot arrangement.
  4. Treat sizable government (e.g. DOE) funding as an upside option you don't rely on.
Here: LIB's whole risk profile hinges on the offtake structure and a US uplisting cutting the cost of capital; the floor-price terms are what let it command a sticky, long-duration multiple.
Watch for

53:31 7. The listed-VC / de-SPAC screen — find the good cohort, read the signals

The repeatable method
  1. Start from the base rate: 90%+ of de-SPACs are terrible — hunt the small cohort that are (or could be) genuinely good businesses.
  2. Demand a big-TAM, disruptive first-mover with a structural edge (platform-agnostic, not a me-too).
  3. Read the insider signal: zero insiders selling — better, insiders/private owners buying as they move into the listed sphere (the opposite of the usual SPAC cash-out).
  4. Take incumbents partnering instead of self-building as third-party validation and de-risking.
  5. Then size it like venture: small, expect dilution / drawdowns / delays, and be prepared to hold 3–5 years.
Here: MRLN ticks every box — platform-agnostic first-mover, GE/GD/Honeywell + DOD partners, zero insider selling — the same pattern that worked on ASTS ($1bn → ~$40–50bn).
Watch for

59:14 8. The dual-use adoption sequence — fund on defense, dream on commercial

The repeatable method
  1. For dual-use tech, recognize the military steps up first — bankrolling, partnering and de-risking the product.
  2. Underwrite the base case on the funded defense pathway that's in front of you; treat the larger, slower commercial market as the "lottery ticket," not the base case.
  3. Favor AI that delivers visible value behind real barriers — AI fused with physical product and a long regulatory lead time is hard to replicate.
Here: MRLN mirrors ASTS — defense funds it now, commercial aviation is the upside; the regulatory lead time + physical retrofit is the moat.
Watch for

1:01:40 9. Probability-weighted bear/base/bull — with an honest $0 bear

The repeatable method
  1. Write explicit bear / base / bull scenarios and assign probabilities, not a single price target.
  2. For near-binary names, recognize that small shifts in those probabilities move the equity a lot — so size accordingly.
  3. Always define the genuine zero: read the capital structure for the "hair" (convertible prefs that sit over the equity, re-strikes that lift the share count) that makes a real $0 bear.
Here: MRLN is framed as a 30–50x+ bull (100x with commercial) against a true-zero bear, with convertible prefs and a September-ADV re-strike as the downside "hair."
Watch for

7:55 10. Scale against the froth — take risk off when you feel most bullish

The repeatable method
  1. On really frothy days, "scale away from what you're feeling" — if you feel super bullish, that's when to take some risk off.
  2. For options specifically, scale out after a large run while they're still out-of-the-money, because the volatility premium is rich and reverses fast.
  3. Keep it personal: match the cut to your own risk tolerance and "sleeping level."
Here: the LODE $7.50 December calls ran +200–250% on directors-buying news; he flagged scaling out before they "cratered" that Friday.
Watch for

Methods distilled from the members-only Contrarian Codex Patreon video (transcript in transcript.txt) for personal study. Not investment advice. © Contrarian Codex / Uzo Capital for source material.